FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average burden										
ı	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     BOLNO PAUL					2. Issuer Name and Ticker or Trading Symbol Wave Life Sciences Ltd. [ WVE ]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
DOLIN	OTAGE												Director		10% O		
(Last)	(F	rirst)	(Middle)	3	3. Date of Earliest Transaction (Month/Day/Year)								Officer below)	(give title	Other ( below)	specify	
C/O WAVE LIFE SCIENCES LTD.,						07/25/2022							President and CEO				
733 CONCORD AVE.																	
						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street)													Line)  X Form filed by One Reporting Person				
CAMBRIDGE MA 02138												Form filed by More than One Reporting					
													Person				
(City)	(8	State)	(Zip)														
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Acc	quired, [	Disp	osed o	f, or Be	neficially	Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,		Code (Instr.				Beneficia Owned Fo	F lly (I ollowing (I	Ownership Orm: Direct O) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
									v	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Share Option (right to buy)	\$2.83	07/25/2022		A		180,000		(1)	07	7/25/2032	Ordinary Shares	180,000	\$0.00	180,000	D		

## **Explanation of Responses:**

1. The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024.

## Remarks:

/s/ Paul B. Bolno

07/27/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).